Seres Therapeutics is laying off approximately 30% of its roughly 103-person workforce as part of a pipeline refocusing initiative. The company is pausing investment in its Phase 2 SER-155 study and shifting focus to earlier-stage programs including SER-603 for inflammatory and immune indications.
All entries for: Biologic
February 11, 2026
Bristol Myers Squibb Co
Negative Outlook
Princeton, NJ
10,000+ employees
We continue to evaluate the impact of the IRA on our results of operations, and it is possible that these changes may result in a material impact on our business and results of operations.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
February 11, 2026
Neurocrine Biosciences Inc
Negative Outlook
San Diego, CA
1,000-5,000 employees
Most recently, in August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law… Lower negotiated prices for AUSTEDO and AUSTEDO XR may increase competitive pressures on INGREZZA, including heightened pricing pressure and potential adverse effects on formulary coverage.
Disease Area: Endocrinology, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
February 9, 2026
Genentech
Layoffs
South San Francisco, CA
10,000+ employees
A California WARN notice revealed that 141 employees were laid off across Genentech’s operations, with the terminations taking effect in August 2025. A company spokesperson attributed the delayed posting to a system glitch.
Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 4, 2026
Regeneron Pharmaceuticals
Neutral Outlook
Tarrytown, NY
10,000+ employees
Further, there have been several recent U.S. Congressional inquiries, executive orders, and recently approved or proposed federal and state legislation, regulations, and policies (in addition to those already in effect) designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the out-of-pocket cost of prescription drugs, and reform government program reimbursement methodologies for drugs. Notably, in 2022 the U.S. Congress passed the Inflation Reduction Act (“IRA”)
Disease Area: Multiple
Drug Type: Biologic, Small Molecule
February 4, 2026
Novo Nordisk
Neutral Outlook
Bagsværd
10,000+ employees
In recent years, there has been a general trend in the United States of pharmacy benefit managers managing the cost of obesity and diabetes care to exert pressure on the price of Novo Nordisk’s and competitors’ products. Furthermore, 2025 saw the finalisation of the second round of negotiations with the US administration on Medicare Part D drug prices under the Inflation Reduction Act. Included in these negotiations were semaglutide based products Ozempic®, Rybelsus® and Wegovy® from Novo Nordisk. The negotiated price for the products in Medicare Part D will go into effect in 2027.
Disease Area: Chronic Disease, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
February 3, 2026
Amgen Inc
Negative Outlook
Thousand Oaks, CA
10,000+ employees
Other operating expenses for the full year included Otezla® intangible asset impairment charges of $1.2 billion, following the selection of Otezla® for Medicare price setting, as part of the Inflation Reduction Act (IRA).
Disease Area: Cardiovascular, Hematology, Metabolic Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
February 3, 2026
GSK
Layoffs
London, UK
10,000+ employees
Up to 350 people across GSK’s U.S. and U.K. workforces could lose their jobs as the pharma reorients its investments with its priorities. The layoffs are expected to affect fewer than 70 individuals in the US, and fewer than 50 in the UK.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
January 19, 2026
Takeda
Layoffs
Tokyo
10,000+ employees
Takeda is laying off 243 employees across its U.S. operations, an effort that will heavily affect its neuroscience commercialization teams.The spokesperson told the media outlet the workforce reduction was part of a “strategic decision” to help the company navigate its upcoming loss of exclusivity for Trintellix, a major depressive disorder drug. That decision also includes “reprioritizing resources to prepare for multiple potential new medication launches in the U.S.”
Disease Area: Multiple
Drug Type: Biologic, Small Molecule